Calidi Biotherapeutics, Inc. income statement

In fiscal 2022, Calidi Biotherapeutics, Inc. reported revenue of $45,000, operating income of −$23.1m (a -51395.6% margin) and net income of −$25.4m, or $29.90 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Calidi Biotherapeutics, Inc.: income statement, annual
Fiscal year	2022Dec 2022
Revenue	0
Research and development	7
Selling, general and administrative	16
Operating income	−23
Interest expense	0
Income before tax	−25
Income tax	0
Net income	−25
Diluted EPS	$29.90
Diluted shares (average)	—
EBITDA	−23

US$ thousands unless shown otherwise. Fiscal quarters.

Calidi Biotherapeutics, Inc.: income statement, quarterly
Quarter	2022 Q4Dec 2022
Revenue	0
Research and development	2,263
Selling, general and administrative	2,425
Operating income	−4,688
Interest expense	100
Income before tax	−7,759
Income tax	−3
Net income	−7,756
Diluted EPS	$50.70
EBITDA	−4,590

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Calidi Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Calidi Biotherapeutics, Inc.